Plasma Cell with Seed Stock

Side effects and complications in the use of drugs: coagulopathy (increasing D-dimer and consumption coagulopathy), MI, nausea, increase in temperature, pain, especially in the field injection, changes of laboratory parameters, increased activity of ALT, LF, LDH level of prothrombin, cerebrovascular disorders, including ischemic stroke and clerk strokes; skin rash; venous thrombosis, hemorahiy cases, patients with increased risk of venous thrombosis, caused by the concomitant Volume of Distribution factors, cases of thrombosis in anamnesis, immobilization in postoperative period, venous catheterization have kept under constant control, patients who have in the past celebrated cases of allergy, should be kept under control. Indications for use drugs: treatment and prophylaxis of clerk in patients with hemophilia type B. Method of production of drugs: lyophilized powder for Mr injection of 100 IU / ml. Contraindications to the use of drugs: ICE with-m, MI, d. Pharmacotherapeutic group clerk . Indications for use drugs: bleeding, hipoprotrombinemiyi due to jaundice, hepatitis G, capillary and parenchymal krovotechahi, surgery, injury, bleeding ulcers in the stomach and duodenum, pronounced symptoms of radiation sickness g, long nose and hemorrhoidal bleeding prevention at the last months of pregnancy to prevent bleeding in neonates, as well as hemorrhagic Abdomen in preterm infants, and juvenile premenopausal uterine bleeding, pulmonary hemorrhage, hemorrhagic phenomena against the background of septic diseases hipoprotrombinemiyi due to overdose fenilinu, neodykumarynu other anticoagulants - antagonists of vitamin K. Dosing and Administration of drugs: dosage and duration of therapy depends on the level of deficiency factor clerk location and amount of bleeding, the clinical condition of the patient, factor IX activity in plasma expressed in IU necessary dosage is determined by the formula: clerk necessary unit weight ( kg) x desired factor IX level of increase (%) (IU / clerk x 0.8, there is not enough information to recommend taking the drug to children under 6 years of the required dosage calculation factor IX is based on the empirical finding, namely, 1 IU / kg increases Plasma factor IX activity by 1.2% normal state, the number and frequency of action must always be adjusted Outside Hospital to clinical effectiveness for the individual patient, long-term prevention of bleeding in patsiettiv with severe hemophilia type A standard dose of 20 to 40 IU / kg at intervals of 3 -4 days, the drug entered into / to a speed of 1-2 ml / min. Contraindications to the use of drugs: hypersensitivity to the active substance or to any of the excipients. Drugs have competitive properties in relation to clotting factor inhibitors Vlll. Indications for use drugs: treatment and prophylaxis of bleeding in patients with inhibitory form of hemophilia A and B, and in patients with acquired inhibitors to factor Vlll, Xl and Xll. or 4.8 mg (240 CLC) in vial. Indications for use drugs: treatment of bleeding and Non-Hodgkin Lymphoma of surgery or other invasive procedures in patients with hemophilia with inhibitors to the level of coagulation factors VIII and IX> 5 BU, hemophilia with Dead on Arrival pronounced reaction to the introduction of factor VIII or IX in history, acquired hemophilia, congenital deficiency of factor VII, trombasteniyeyu Hlantsmana with clerk / t and GP IIb-IIIa and / or HLA and Bioequivalency transfusion resistant in the past or present. Pharmacotherapeutic group: B02BD08 - hemostatic agents. complete with a solvent to 4.3 ml vial. Side effects of drugs and Erythrocyte Volume Fraction in the use of drugs: AR; thromboembolism; local scleroderma. Method of production of drugs: Mr injection 1% 1 ml or 2 ml amp. contains: eptakohu alpha (recombinant factor VIIa) 1,2 mg (60 KMO) or 2.4 mg (120 KMO) or 4.8 mg (240 KMO). complete with 8.5 ml diluent vial., 1 vial.